quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 26, 2026

AGNC (AGNC) Q2 2025 Earnings Call Transcript

View original at finance.yahoo.com
AGNC (AGNC) Q2 2025 Earnings Call Transcript Image source: The Motley Fool. Date Tuesday, July 22, 2025 at 8:30 a.m…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AGNC has no plans to grow for the sake of growing; growth is tied to accretive capital raising

    80% confidence
  • Expected MBS net supply for 2025 is approximately $200 billion at the low end of forecasts

    80% confidence
  • GSE privatization must not widen mortgage spreads and should potentially tighten them

    80% confidence
  • The outlook improved in Q2 2025 due to manageable MBS supply, growing MBS demand, stabilizing spreads at cheap levels, and cautious GSE reform approach

    80% confidence
  • GSE reform will follow a do-no-harm approach with no upward pressure on mortgage rates

    80% confidence
  • AGNC has the lowest operating costs in the industry at 111 basis points

    80% confidence
  • Marginal investments are expected to generate high teens returns, somewhere between 18% to 20%

    80% confidence
  • Federal Reserve quantitative tightening expected to end relatively soon, possibly through year-end 2025

    80% confidence
  • Net spread and dollar roll income expected in range of mid- to high $0.30s to low to mid-$0.40s per share

    80% confidence
  • The U.S. government will maintain implicit guarantees for Fannie Mae and Freddie Mac during privatization

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
AGNC (AGNC) Q2 2025 Earnings Call Transcript — Source | Via News | pt.VIA.NEWS